Date |
Title |
Download |
| 2007
|
12.10.07 |
Vion Presents Preliminary
Data from its Pivotal Phase II Trial of Cloretazine® (VNP40101M)
in Acute Myelogenous Leukemia at ASH Annual Meeting |
|
12.6.07 |
Vion To Present Preliminary
Data on its Pivotal Phase II Trial of Cloretazine® (VNP40101M)
at the American Society of Hematology Meeting. Company to Hold
Conference Call on Monday, December 10, 2007 |
|
12.4.07 |
Vion Announces Initiation
of Clinical Trial of Cloretazine® (VNP40101M) in Combination
with Stem Cell Transplantation |
|
11.7.07 |
Vion Reports 2007 Third
Quarter and Nine-Month Results |
|
11.6.07 |
Vion to Host Conference
Call To Discuss 2007 Third Quarter and Nine-Month Financial Results |
|
9.18.07 |
Vion Receives Notice from
Nasdaq |
|
9.17.07 |
Vion Announces Initiation
of a Phase I/II Trial of Cloretazine® (VNP40101M) in Combination
with Temodar® in Adult Brain Tumors |
|
9.10.07 |
Vion To Present at 20th
Annual Bear Stearns Healthcare Conference |
|
8.15.07 |
Vion Pays Interest on
7.75% Convertible Senior Notes |
|
8.15.07 |
Vion Completes Accrual
of 85 Patients to its Pivotal Phase II Trial of Cloretazine® (VNP40101M)
in Elderly AML |
|
8.08.07 |
Vion Reports 2007 Second
Quarter and Six-Month Results |
|
8.07.07 |
Vion to Host Conference
Call To Discuss 2007 Second Quarter and Six-Month Financial Results |
|
6.25.07 |
Vion to Hold Annual
Meeting of Stockholders |
|
6.11.07 |
Vion Presents Clinical
Data from a Phase II Trial of Cloretazine® (VNP40101M) in
Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting |
|
5.23.07 |
Vion Announces Suspension
of Phase III Trial in Relapsed AML |
|
5.8.07 |
Vion Reports 2007 First Quarter Financial Results |
|
5.4.07 |
Vion to Host Conference Call To Discuss 2007
First Quarter Financial Results |
|
4.23.07 |
Vion to Present at Fortis Bank Biotechnology
Conference |
|
4.13.07 |
Vion Presents Data on Cloretazine® (VNP40101M)
at the 100th Annual Meeting of the American Association of Cancer
Research (AACR) |
|
4.11.07 |
Dr. James Tanguay Joins Vion Pharmaceuticals’ Senior
Management Team |
|
3.22.07 |
Vion Extends Manufacturing Agreement with SAFC
for Cloretazine® (VNP40101M) |
|
3.2.07 |
Vion Reports 2006 Fourth Quarter and Year-End
Financial Results |
|
3.1.07 |
Vion to Host Conference Call To Discuss Fourth
Quarter and Year-End Financial Results |
|
2.20.07 |
Vion Completes Private Placement of Convertible
Notes and Warrants |
|
2.14.07 |
Vion Enters into an Agreement to Sell Convertible
Senior Notes and Warrants |
|
1.25.07 |
Vion Proceeding to Second Stage of Pivotal
Phase II Trial of Cloretazine® (VNP40101M) in Elderly AML |
|
| 2006
|
12.13.06 |
Vion Enters into Manufacturing Agreement for
Cloretazine® (VNP40101M) with Ben Venue Laboratories |
|
12.11.06 |
Vion Presents Data on Cloretazine (VNP40101M)
at the 48th Annual American Society of Hematology (ASH) Meeting |
|
11.13.06 |
Vion Reaches Midpoint of Patient Accrual to
Cloretazine® (VNP40101M) Phase III Trial |
|
11.9.06 |
Vion to Host Conference Call To Discuss Third
Quarter and Nine Month Financial Results |
|
11.9.06 |
Vion Reports 2006 Third Quarter and Nine-Month
Financial Results |
|
11.6.06 |
Vion to Present at Rodman & Renshaw and
CIBC World Markets Conferences |
|
10.30.06 |
Vion to Present at C.E. Unterberg, Towbin Life
Sciences Conference |
|
10.26.06 |
Vion Presents Initial Data from a Phase II
trial of Cloretazine® (VNP40101M) in Patients with Relapsed
or Refractory Small Cell Lung Cancer |
|
9.21.06 |
Vion to Present at UBS Global Life Sciences
Conference |
|
9.11.06 |
Vion to Present at Bear Stearns and Think Equity
Conferences |
|
8.8.06 |
Vion Reports 2006 Second Quarter Financial
Results |
|
8.8.06 |
Vion to Host Conference Call to Discuss Second
Quarter Financial Results |
|
6.17.06 |
Aileen Ryan Joins Vion's Senior Management
Team |
|
6.28.06 |
Ian Williams Elected to Vion Board of Directors |
|
6.26.06 |
Vion to Hold Annual Meeting of Stockholders |
|
6.5.06 |
Vion Presents Data on Cloretazine® In Elderly De
Novo Acute Myelogenous Leukemia at ASCO Meeting |
|
5.31.06 |
Vion Provides Update for Clinical and Preclinical
Programs |
|
5.30.06 |
Vion to Hold Conference Call |
|
5.24.06 |
Vion Initiates Pivotal Phase 2 Trial of Single Agent Cloretazine® in
Elderly Patients with De Novo Poor-Risk Acute Myelogenous
Leukemia |
|
5.8.06 |
Vion Reports 2006 First Quarter Financial Results |
|
4.4.06 |
Vion Presents Preclinical Data on Cloretazine® (VNP40101M),
a Hypoxia-Selective Compound (VNP40541) and Hydrazones at AACR
Meeting |
|
2.28.06 |
Vion Reports 2005 Year-End and Fourth Quarter Financial Results |
|
1.31.06 |
Vion Announces Plans to Conduct a Pivotal Phase 2 Trial of Cloretazine® in
Elderly Poor-Risk Acute Myelogenous Leukemia |
|
1.30.06 |
Vion to Host Conference Call |
|
1.23.06 |
Vion Receives Orphan Drug Designation for Cloretazine® in
Europe for Treatment of Acute Myeloid Leukemia |
|
1.10.06 |
Meghan Fitzgerald Joins Vion's Senior Management Team |
|
We hope we have provided you with answers to some of your questions. If you have a specific question please contact us.
